Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 5/20 | 0.34 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8415470 | 0.81 | PDE2A (0.47) | PDE2ANOTUMCES2TAS2R14KIF11 | |
| SCHEMBL799856 | 0.81 | KIF11 (0.44) | PDE2ANOTUMS1PR1CES2TAS2R14 | |
| SCHEMBL24722133 | 0.79 | AR (0.34) | PDE2ACES2FFAR1FFAR4AR | |
| SCHEMBL19426786 | 0.78 | PDE2A (0.38) | PDE2ANOTUMS1PR1CES2CTSS | |
| SCHEMBL1538689 | 0.77 | CES2 (0.50) | PDE2ANOTUMS1PR1CES2TAS2R14 | |
| SCHEMBL1927914 | 0.75 | TSHR (0.46) | KIF11 | |
| SCHEMBL30786333 | 0.75 | TSHR (0.46) | KIF11 | |
| SCHEMBL25767550 | 0.74 | PDE2A (0.38) | PDE2ANOTUMCES2KIF11 | |
| SCHEMBL1995277 | 0.74 | CES2 (0.40) | PDE2ANOTUMS1PR1CES2TAS2R14 | |
| SCHEMBL25767609 | 0.74 | PDE2A (0.41) | PDE2ANOTUMS1PR1CES2TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759807-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190194208-A1 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759807-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | PDE2A 916/4885CNR1 231/4885CNR2 429/4885 |
| US-20190194208-A1 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | PDE2A 916/4885CNR1 231/4885CNR2 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.